ArticleClinical & developmental immunology2013
Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort.
Article in Clinical & developmental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 85 citations in OpenAlex.
- Clinical significance of anti-dense fine speckled 70 antibodies in dense fine speckled immunofluorescence positive patients, systemic autoimmune rheumatic diseases, and controls.The Indian journal of medical research · 2026Article
- VII Brazilian Consensus guidelines for the detection and interpretation of anti-cell autoantibodies on HEp-2 cells.Advances in rheumatology (London, England) · 2025Review
- CytoBead ANA 2 assay - a novel method for the detection of antinuclear antibodies.Scientific reports · 2025Article
- Evaluation of Positive Cases for Dense Fine Speckled (DFS) Immunofluorescence Pattern and Anti-DFS70 Antibodies.Pakistan journal of medical sciences · 2025Article
- Clinical Significance of Antibodies to DFS70 in Immunoinflammatory Rheumatic Diseases.Doklady. Biochemistry and biophysics · 2024Article
- The Nuclear Dense Fine Speckled (DFS) Immunofluorescence Pattern: Not All Roads Lead to DFS70/LEDGFp75.Diagnostics (Basel, Switzerland) · 2023Article
- Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study.Rheumatology international · 2022Observational
- Low Prevalence of Anti-DFS70 Antibodies in Children With ANA-Associated Autoimmune Disease.Frontiers in pediatrics · 2022Article
- Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress.Biomarker insights · 2022Article
- How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative.Immunologic research · 2021Article
- [Clinical significance of determination of DFS70 antibodies to rule out connective tissue diseases].Zeitschrift fur Rheumatologie · 2020Article
- Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: many lessons learned but still many questions.Auto- immunity highlights · 2020Review
- Anti-DFS70 Antibodies Among Patient and Healthy Population Cohorts in China: Results From a Multicenter Training Program Showing Spontaneous Abortion and Pediatric Systemic Autoimmune Rheumatic Diseases Are Common in Anti-DFS70 Positive Patients.Frontiers in immunology · 2020Article
- Simultaneous Distinction of Monospecific and Mixed DFS70 Patterns During ANA Screening with a Novel HEp-2 ELITE/DFS70 Knockout Substrate.Journal of visualized experiments : JoVE · 2018Article
- Recognition and Relevance of Anti-DFS70 Autoantibodies in Routine Antinuclear Autoantibodies Testing at a Community Hospital.Frontiers in medicine · 2018Article
- Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate.Auto- immunity highlights · 2017Article
- Detection of autoantibodies to DSF70/LEDGFp75 in Mexican Hispanics using multiple complementary assay platforms.Auto- immunity highlights · 2017Article
- The Clinical Relevance of Anti-DFS70 Autoantibodies.Clinical reviews in allergy & immunology · 2017Review
- Measurement of anti-DFS70 antibodies in patients with ANA-associated autoimmune rheumatic diseases suspicion is cost-effective.Auto- immunity highlights · 2016Article
- Recognition of the dense fine speckled (DFS) pattern remains challenging: results from an international internet-based survey.Auto- immunity highlights · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze the clinical value of anti-DFS70 antibodies in a cohort of patients undergoing routine antinuclear antibodies (ANAs) testing.
methodsSera with a dense fine speckled (DFS) indirect immunofluorescence (IIF) pattern from 100 consecutive patients and 100 patients with other IIF patterns were tested for anti-DFS70 antibodies by a novel chemiluminescence immunoassay (CIA) and for ANA by ANA Screen ELISA (both INOVA).
resultsAmong the 100 patients with a DFS IIF pattern, 91% were anti-DFS70 positive by CIA compared to 3% in the comparator group (P < 0.0001). The CIA and IIF titers of anti-DFS antibodies were highly correlated (rho = 0.89). ANA by ELISA was positive in 35% of patients with the DFS IIF pattern as compared to 67% of patients with other patterns (P < 0.0001). Only 12.0% of patients with DFS pattern and 13.4% with DFS pattern and anti-DFS70 antibodies detected by CIA had systemic autoimmune rheumatic disease (SARD). Only 5/91 (5.5%) patients with anti-DFS70 antibodies had SARD and their sera were negative on the ANA Screen ELISA.
conclusionAlthough anti-DFS70 antibodies cannot exclude the presence of SARD, the likelihood is significantly lower than in patients with other IIF patterns and should be included in test algorithms for ANA testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.